Prostate cancer screening company Prostate Conditions Education Council (PCEC) said on Monday that it is providing free prostate cancer testing to men across the country following the recent fall in delayed diagnosis due to fewer doctor visits and reduced testing in the face of ongoing COVID-19 pandemic.
Prostate cancer is the second leading cause of cancer death in men, but easily treated when caught early, but too often it is not diagnosed early. The Council's new programme allows for men to gain access to a prostate specific antigen (PSA) blood test by visiting a national network for laboratories for the simple blood test and those who are unable to visit a laboratory. The free testing programme will take place during September and will continue throughout the fall season until the resources for the programme are depleted.
Additionally, the Council has aligned with at-home digital screening provider imaware to promote testing so that men can take assess their prostate cancer risk. The families can sign up for the free prostate cancer screening by visiting www.prostateevents.org.
Based in Houston, Texas, imaware has provided an essential healthcare service to thousands of Americans for COVID-19, cardiovascular disease, prostate cancer and autoimmune disorders.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval